2026年港股IPO的四大新趋势

Core Viewpoint - The Hong Kong IPO market is experiencing a surge in new listings, particularly in the semiconductor and biopharmaceutical sectors, with expectations for continued strong performance in 2026 [1][2]. Group 1: Trends in the IPO Market - In January 2026, 12 new stocks have been listed on the Hong Kong market, including several semiconductor companies and biopharmaceutical firms, indicating a trend of concentrated listings in these sectors [1]. - The 2025 Hong Kong market saw 117 new stocks listed, raising a total of 285.99 billion HKD, surpassing the expected fundraising amount of 23.31 billion HKD, with an average oversubscription of approximately 200 million HKD per stock [1]. - A significant portion of the fundraising in 2025 was dominated by A+H shares, with eight companies alone accounting for 49.82% of the total IPO fundraising [1]. Group 2: Specific Sector Insights - The surge in semiconductor and AI-related companies is attributed to their high capital expenditures and R&D costs, necessitating financing from the capital markets [2]. - The Hong Kong IPO rules, particularly the 18C and 18A regulations, are tailored to accommodate technology and biopharmaceutical companies, with at least 31 companies aiming to list under the 18A rules and 16 under the 18C rules [2]. Group 3: Market Dynamics - The trend of A+H shares is expected to continue but with a reduced proportion compared to 2025, as the concentration of fundraising is anticipated to decrease [2]. - Some H shares are expected to return to A shares as the A-share listing process normalizes and reforms are implemented [3]. - The influx of international capital into the Hong Kong IPO market is driven by a broader search for diversification beyond US dollar assets, with over half of the cornerstone investors in 2025 being international [3].